Aykut Öztürk

Aykut Öztürk

Auto-generated profile, based on publicly available information

Aykut Öztürk

Sakarya University, Faculty of Medicine, Department of Pharmacology, Sakarya/Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Anais da Academia Brasileira de Ciências
Verified
Journal Article
Open access
MTMehmet H. Tanyeri
Mehmet H. Tanyeri
MBMehmet E. Buyukokuroglu
Mehmet E. Buyukokuroglu
PTPelin Tanyeri
Pelin Tanyeri
OMOguz Mutlu
Oguz Mutlu
AOAykut Ozturk
Aykut Ozturk
RKRumeysa K. Kaya
Rumeysa K. Kaya
Mirabegron is the first b3-adrenoceptor agonist to enter clinical practice and has been approved for the treatment of symptoms of OAB. The aim of this study is to investigate whether the mirabegron has an effect on depression, anxiety, learning, and memory. We investigated the effects of mirabegron on depression, anxiety, learning and memory by using forced swimming test, elevated plus maze test, passive avoidance and Morris water maze in mice. Imipramine and mirabegron (3, 6 and 9 mg/kg) significantly reduced immobility time in forced swimming test. Diazepam and mirabegron (3, 6 and 9 mg/kg) significantly increased the time spent in open arms and the number of entries to the open arms in elevated plus maze test. Furthermore, cognitive performance impaired with scopolamine has been significantly improved with 9 mg/kg mirabegron. Mirabegron (6 and 9 mg/kg) significantly increased the time spent in the target quadrant in naive mice. While scopolamine significantly increased the swimming speed, mirabegron (9 mg/kg) significantly decreased the swimming speed in scopolamine-treated mice. Mirabegron might be clinically useful for the treatment of OAB in elderly patients that should use drugs against depression and anxiety, without disrupt learning and memory.

1 December 2021 in Online Türk Sağlık Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
SSSinan Saral
Sinan Saral
ATAtilla Topçu
Atilla Topçu
ASAYŞEGÜL SÜMER
AYŞEGÜL SÜMER
AKAli Koray Kaya
Ali Koray Kaya
AÖAykut Öztürk
Aykut Öztürk
EPEsra Pinarbaş
Esra Pinarbaş
Objective: The antidepressant agomelatine agent is a melatonin receptor (MT1 and MT2) agonist and a serotonin receptor (5-HT2C) antagonist. Increasing evidence shows that agomelatine has neuroprotective and neuromodulatory effects. In this study, the potential effects of agomelatine in rats with scopolamine-induced cognitive impairment were investigated.Materials and Methods: Adult male rats were administered scopolamine (1 mg/kg) and agomelatine (40 mg/kg) for 21 days. After drug administration, rats were subjected to new object recognition (NOR) and Morris water maze (MWM) tests in order to evaluate cognitive behaviors. In addition, brain-derived neurotrophic factor (BDNF) and acetylcholine (ACh) levels in the hippocampus and prefrontal cortex were evaluated.Results: Scopolamine significantly decreased both spatial memory and discrimination index (p0.05). In addition, agomelatine significantly increased BDNF levels in both hippocampus and prefrontal cortex compared to the scopolamine group (p<0.05, p0.05).Conclusion: Taken together, these results demonstrated that agomelatine plays a important role in alleviating scopolamine-induced memory impairment. Therefore, we suggest that agomelatine may be a potential agent in the prevention of cognitive impairment.

21 February 2022 in Sakarya Medical Journal
Verified
Journal Article
Open access
MTMehmet Hanifi Tanyeri̇
Mehmet Hanifi Tanyeri̇
MBMehmet Emin Büyükokuroğlu
Mehmet Emin Büyükokuroğlu
PTPelin Tanyeri̇
Pelin Tanyeri̇
AÖAykut Öztürk
Aykut Öztürk
RKRümeysa Keleş
Rümeysa Keleş
OMOguz Mutlu
Oguz Mutlu
Objective: Overactive bladder (OAB) constitutes the majority of childhood incontinence causes. Oxybutynin is an antimuscarinic agent frequently used for children in the treatment of OAB. This study aimed to investigate the effects of an antimuscarinic drug oxybutynin on learning and memory. Materials and Methods: We assessed the effects of oxybutynin on learning and memory functions using the Passive Avoidance (PA) and the Morris Water Maze (MWM) Test in mice. Results: Oxybutynin treatment (1 mg/kg, 2 mg/kg, and 4 mg/kg) did not show a significant difference in the retention time on the second day compared to the control and oxybutynin (4 mg/kg) significantly prolonged the retention time in scopolamine-treated mice. In the MWM Test, oxybutynin (1 mg/kg, 2 mg/kg, and 4 mg/kg) has no effect on the time spent in the target quadrant. Scopolamine (0.6 mg/kg) alone significantly reduced time spent in the target quadrant, but oxybutynin (4 mg/kg) significantly prolonged time spent in the target quadrant in scopolamine-treated mice. Also, scopolamine significantly increased the mean distance to the escape platform, while oxybutynin (4 mg/kg) significantly decreased the mean distance to the escape platform in scopolamine-treated mice. Conclusion: In our study, oxybutynin did not affect learning and memory, but it plays a role ameliorating the learning and memory deficits. The results of this study show that the use of oxybutynin in patients with OAB does not affect learning and memory.